We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Janssen Prevails in Battle With Mylan Over Schizophrenia Drug Patent
Janssen Prevails in Battle With Mylan Over Schizophrenia Drug Patent
A New Jersey federal judge has ruled that Mylan cannot pursue a generic version of Janssen Pharmaceuticals’ injectable schizophrenia drug, Invega Trinza.